The comfort and efficiency offered by next generation diabetes products is expected to attract the patients with higher purchasing power and fuel the innovations and market growth.

Portland, OR -- (SBWire) -- 06/23/2017 --Next Generation Diabetes Therapy and Drug Delivery Market report, published by Allied Market Research, forecasts that the global market was valued at $617 million in 2015 and is expected to garner $9,673 million by 2022, registering a CAGR of 41.1% during the forecast period 2016 - 2023. North America is the highest contributor in the next generation diabetes therapy and drug delivery market; however, Asia-Pacific is witnessing the highest growth rate.

Early buyers will receive 20% customization on this report

Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems, such as oral and inhalable insulin, help introduce insulin into the patients body without causing pain and reduce the risk of skin irritation, owing to frequent use of needles. Advancements in diabetes therapy systems, such as insulin patch, continuous glucose monitoring (CGM) system, and artificial pancreas, are frequently used to detect the glucose levels and adjust the insulin levels to manage the change in glucose levels.

Get Sample: https://www.alliedmarketresearch.com/request-sample/2098

Rise in the number of diabetics and the benefits of using advanced diabetic devices, such as artificial pancreas and insulin patches over conventional products, are expected to boost the growth of next generation diabetes therapy and drug delivery market. Furthermore, the increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products areanticipated to fuel the market growth. The rise in healthcare expenditure in the developing countries, such as India and China, is expected to provide opportunities for market expansion. However, lack of awareness, less variability in products, and cost restrains in the developing regions are expected to hamper the market growth.

CGM system is a well-established product and dominates the market, attributed to the presence of a large patient base suffering from diabetes with highest share in 2015, and is anticipated to continue this trend in the future, in terms of revenue. Advantages of these systems as compared to conventional diabetic products are ease of usage and efficient & early detection of change in blood glucose levels, which are expected to boost the growth of this segment.

Diagnostics/clinics was the highest contributor and is anticipated to continue its dominance during the analysis period, and has accounted for about half of the share of the global market in 2015, due to the increase in procurement of the products from diagnostics and clinics by diabetic patients.

In 2015, North America displayed maximum contribution to the total revenue generated, while Asia-Pacific is expected to witness the highest CAGR of 50.2%, due to rise in disposable income, improvement in healthcare expenditure, and increase in adoption rate of advanced diabetic products.

Key Findings of Next Generation Diabetes Therapy and Drug Delivery Market

Artificial pancreas segment is projected to grow at the highest rate during the analysis period.

CGM system was the highest revenue-generating segment, and is expected to continue its dominance in future.

North America dominated global next generation diabetes therapy and drug delivery market, and is projected to grow at a CAGR of 40%.

India is expected to grow highest in the Asia-Pacific region, registering a CAGR of 51.1%.

Diagnostic/clinic segment was the highest end user contributor towards the market during the analysis period.

Do Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2098

The key companies profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Inc., Senseonics Holding, Inc., Medtech, and Johnson & Johnson.